US · Healthcare · Biotechnology
EPS came in at -1.23 against a street estimate of -2.06 — a beat of 40.3%.
Analysts rate Nektar Therapeutics a buy (4 buy, 3 hold, 1 sell out of 8) with an average price target of $144.40.
| Fund | Stake |
|---|---|
| FMR Inc | 12.60% |
| Bvf Inc | 7.50% |
| Two Seas Capital LP | 5.74% |
| Two Sigma Investments LLC | 3.52% |
| Vanguard Capital Management, LLC | 3.51% |
| Prosight Management, LP | 2.37% |
| BlackRock Inc | 2.03% |
| Morgan Stanley - Brokerage Accounts | 1.93% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 NEKTAR THERAPEUTICS FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Nektar Therapeutics (Nasdaq: NKTR) • Filing Date: September 8, 2026 • Headquarters: | 2026-09-08 |
| Quarterly report · Q2 2026 NEKTAR THERAPEUTICS - FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and investments: $1,023.4 million as of June 30, 20 | 2026-08-14 |
| Results announced · Q3 2026 NEKTAR THERAPEUTICS – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and investments: $1,023.4 million as of June 30, 2026, up from $245.8 millio | 2026-08-13 |
| Shareholder vote results · Q2 2026 NEKTAR THERAPEUTICS – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Stockholder Meeting held June 4, 2026 • Director election: Howard W. Robin elected | 2026-06-05 |
| Quarterly report · Q1 2026 NEKTAR THERAPEUTICS – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and investments: $731.6 million as of March 31, 2026 ($15.1 million cash + $419.0 | 2026-05-08 |
| Material agreement · Q2 2026 NEKTAR THERAPEUTICS - 8-K SUMMARY HEADLINE NUMBERS • Company established equity distribution agreement for up to $150,000,000 in common stock offeri | 2026-05-08 |
| Proxy statement · Q2 2026 NEKTAR THERAPEUTICS – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect one director with term expiring at 2029 | 2026-04-24 |
| Annual report FY2025 NEKTAR THERAPEUTICS – 2025 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): approximately $318 | 2026-03-13 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 15 effective Jun 9, 2025 | 2025-06-09 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nektar Therapeutics — free to start.
Google PlayApp StoreData updated 2026-09-18.